Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAT_PB: Biomarkers and Palbociclib in Cancer-Associated Thromboembolism
NCT06065592Phase 1Unknown
- Sponsor
- Lebanese University
- Start
- Feb 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of palbociclib in cancer-associated thrombosis (CAT) (5 arms), sponsored by Lebanese University. Primary endpoints: Venous Thromboembolism (VTE) Events up to 60 months, Assessment of Cancer Progression up to 60 months and 2 more. Status: unknown.
02
Drugs
palbociclib
03
Conditions
cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on NCT06065592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065592.